论文部分内容阅读
目的观察依达拉奉治疗外伤性脑血管痉挛患者的临床治疗效果。方法采用前瞻性对比研究,将180例外伤性脑血管痉挛患者,按程度分为轻、中、重组,每组再随机分为依达拉奉治疗组和生理盐水对照组。两组均采用相同的脱水、脑脊液置换等治疗和对症处理;治疗组加用依达拉奉30mg,2次/日,静脉滴注,连用14d,观察两组临床疗效。结果依达拉奉对于轻度脑血管痉挛患者,治疗组和对照组相比差异无统计学意义(P﹥0.05);而中、重组,对脑血管痉挛缓解及外伤性脑梗塞发生率,两者差异有统计学意义(P﹤0.01);患者3月后GOS评价,治疗组临床疗效明显好于常规治疗组(P﹤0.01)。结论依达拉奉早期应用治疗外伤性中重度脑血管痉挛有明显临床疗效,可降低外伤性脑梗塞发生率,改善患者预后。
Objective To observe the clinical efficacy of edaravone in the treatment of traumatic cerebral vasospasm. Methods A prospective comparative study of 180 patients with traumatic cerebral vasospasm was divided into mild, moderate and severe groups according to the degree. Each group was then randomly divided into edaravone treatment group and saline control group. The two groups were treated with the same dehydration, replacement of cerebrospinal fluid, and symptomatic treatment. The treatment group was treated with edaravone 30 mg twice daily for intravenous drip for 14 days. The clinical effects were observed in both groups. Results Edaravone for mild cerebral vasospasm patients, the treatment group and the control group, no significant difference (P> 0.05); and in the reorganization, the ease of cerebral vasospasm and the incidence of traumatic cerebral infarction, two (P <0.01). After 3 months of GOS evaluation, the clinical efficacy of the treatment group was significantly better than that of the conventional treatment group (P <0.01). Conclusion Early application of edaravone in the treatment of traumatic moderate and severe cerebral vasospasm has a significant clinical effect, can reduce the incidence of traumatic cerebral infarction and improve prognosis.